IRIS
BUTI, Sebastiano
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 5.867
EU - Europa 4.299
AS - Asia 1.510
AF - Africa 52
SA - Sud America 10
OC - Oceania 7
Continente sconosciuto - Info sul continente non disponibili 3
Totale 11.748
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 5.840
IE - Irlanda 1.565
SE - Svezia 1.223
IT - Italia 895
SG - Singapore 766
CN - Cina 581
FI - Finlandia 132
AT - Austria 126
DE - Germania 125
IN - India 69
CI - Costa d'Avorio 44
BE - Belgio 42
GB - Regno Unito 32
FR - Francia 27
CZ - Repubblica Ceca 25
TR - Turchia 24
UA - Ucraina 24
CA - Canada 22
NL - Olanda 22
IR - Iran 21
RU - Federazione Russa 16
JP - Giappone 15
HK - Hong Kong 11
ES - Italia 9
CH - Svizzera 7
AU - Australia 6
BR - Brasile 6
MA - Marocco 6
KR - Corea 5
LU - Lussemburgo 5
LT - Lituania 4
MX - Messico 4
PH - Filippine 4
VN - Vietnam 4
BG - Bulgaria 3
CO - Colombia 3
GR - Grecia 3
HR - Croazia 3
IL - Israele 3
MD - Moldavia 3
PL - Polonia 3
A1 - Anonimo 2
ID - Indonesia 2
KZ - Kazakistan 2
OM - Oman 2
PT - Portogallo 2
BS - Bahamas 1
EG - Egitto 1
EU - Europa 1
MK - Macedonia 1
NZ - Nuova Zelanda 1
PY - Paraguay 1
RO - Romania 1
SK - Slovacchia (Repubblica Slovacca) 1
TW - Taiwan 1
ZA - Sudafrica 1
Totale 11.748
Salva come PNG Salva come JPEG
Città #
Chandler 1.913
Dublin 1.550
Boardman 552
Ashburn 546
Singapore 524
Princeton 299
Beijing 196
Shanghai 193
Vienna 126
Ann Arbor 122
Helsinki 113
New York 104
Milan 97
Parma 97
Des Moines 88
Santa Clara 79
Wilmington 69
Rome 61
Bologna 56
Bremen 50
Abidjan 44
Verona 34
Brussels 33
Los Angeles 31
Dearborn 29
Pune 29
Chicago 26
Jacksonville 25
Seattle 24
Nanjing 20
Genoa 18
Florence 17
London 17
Reggio Emilia 17
Modena 16
San Mateo 15
Torrile 14
Dallas 13
Arezzo 12
Brno 12
Munich 12
Olomouc 12
Washington 12
Atlanta 11
Izmir 11
Jinan 11
Borås 10
Fairfield 10
Naples 10
Turin 10
Fremont 9
Rockville 9
Scandiano 9
Toronto 9
Trento 9
Woodbridge 9
Falls Church 8
Fort Worth 8
Guangzhou 8
Hangzhou 8
Nanchang 8
Norwalk 8
Tokyo 8
Forest City 7
Houston 7
Istanbul 7
Kunming 7
Rio Saliceto 7
Sassuolo 7
Shenyang 7
Wuhan 7
Assago 6
Boston 6
Brescia 6
Hebei 6
Hong Kong 6
Louvain-la-Neuve 6
Meknes 6
Padova 6
Prineville 6
Sacramento 6
Tianjin 6
West Jordan 6
Amsterdam 5
Cavriago 5
Chennai 5
Deiva Marina 5
Frankfurt am Main 5
Gela 5
Hefei 5
Kish 5
Menlo Park 5
Miami 5
Mumbai 5
New Delhi 5
Reggio Nell'emilia 5
Verdellino 5
Ardea 4
Busto Arsizio 4
Central 4
Totale 7.710
Salva come PNG Salva come JPEG
Nome #
The circulating pool of functionally competent NK and CD8+ cells predicts the outcome of anti-PD1 treatment in advanced NSCLC 113
PREDICTIVE AND PROGNOSTIC VALUE OF CLINICAL AND MOLECULAR FEATURES IN PATIENTS UNDERGOING PULMONARY METASTASECTOMY FROM RENAL CELL CARCINOMA 101
Correlations between tumor-infiltrating and circulating lymphocyte subpopulations in advanced renal cancer patients treated with nivolumab 88
238P Exploring blood immune cell dynamics to unravel the immunomodulatory effect of radiotherapy in NSCLC patients undergoing immune checkpoint inhibitors 84
Early primary tumor response in metastatic RCC patients treated with immune checkpoint inhibitors-based combinations 81
READY: Real-world data from an Italian compassionate use program of avelumab first-line maintenance (1LM) treatment for locally advanced or metastatic urothelial carcinoma (la/mUC) 80
Soluble PD-L1 and Circulating CD8+PD-1+ and NK Cells Enclose a Prognostic and Predictive Immune Effector Score in Immunotherapy Treated NSCLC patients 74
LONGITUDINAL MONITORING OF RADIOMIC AND BLOOD IMMUNE-INFLAMMATORY DESCRIPTORS AS A NON-INVASIVE APPROACH TO PREDICT ICI EFFICACY IN ADVANCED NSCLC PATIENTS 73
The Prognostic Role of High Blood Cholesterol in Advanced Cancer Patients Treated With Immune Checkpoint Inhibitors 73
ALK and ROS1 rearrangements tested by fluorescence in situ hybridization in cytological smears from advanced non-small cell lung cancer patients 73
Dynamic Profiling of Blood Immunophenotypes and Radiomic Features to Predict Immunotherapy Response in Advanced Non-small Cell Lung Cancer 71
The Urinary Microbiome and Anticancer Immunotherapy: The Potentially Hidden Role of Unculturable Microbes 66
Immune context characterization and heterogeneity in primary tumors and pulmonary metastases from renal cell carcinoma 66
Another side of the association between body mass index (BMI) and clinical outcomes of cancer patients receiving programmed cell death protein-1 (PD-1)/ Programmed cell death-ligand 1 (PD-L1) checkpoint inhibitors: A multicentre analysis of immune-related adverse events 65
Chronically administered immunotherapy with low-dose IL-2 and IFN-α in metastatic renal cell carcinoma: A feasible option for patients with a good prognostic profile 65
Circulating immune-profile as predictor of outcome in advanced NSCLC patients treated with Nivolumab 64
Clinical and hematologic parameters address the outcomes of non-small-cell lung cancer patients treated with nivolumab 64
P1.15-04 Dynamic Profiling of Blood Immunophenotypes and Radiomic Features to Predict Immunotherapy Response in Advanced Non-small Cell Lung Cancer 63
INfluenza Vaccine Indication during therapy with Immune checkpoint inhibitors: A multicenter prospective observational study (INVIDIa-2) 63
1352P A highly predictive blood-radiomics classifier in advanced NSCLC treated with immunotherapy 63
17P Dynamic changes of CT-radiomic and systemic immune-inflammatory features predict the response to immune checkpoint inhibitors in advanced NSCLC patients 63
Monitoring cfDNA in plasma and in other liquid biopsies of advanced EGFR mutated NSCLC patients: A pilot study and a review of the literature 61
CLINICAL PREDICTORS OF 30-DAY MORTALITY IN HOSPITALIZED PATIENTS WITH LUNG CANCER: A RETROSPECTIVE SINGLE-CENTER OBSERVATIONAL STUDY 59
LA PRATICA CLINICA - Everolimus nel carcinoma renale papillare 58
Antibiotic-dependent effect of probiotics in patients with non-small cell lung cancer treated with PD-1 checkpoint blockade 57
Changes in lymphocyte count induced by repeated cycles with low-dose interleukin-2 and interferon-α in 146 patients with renal cell carcinoma. 57
Analysis of a panel of druggable gene mutations and of ALK and PD-L1 expression in a series of thymic epithelial tumors (TETs) 57
CEA and CYFRA 21-1 as prognostic biomarker and as a tool for treatment monitoring in advanced NSCLC treated with immune checkpoint inhibitors 57
Clinical Impact of COVID-19 Outbreak on Cancer Patients: A Retrospective Study 57
The right immune-modulation at the right time: thymosin α1 for prevention of severe COVID-19 in cancer patients 54
Clinical impact of COVID-19 in a single-center cohort of a prospective study in cancer patients receiving immunotherapy 53
Primo caso di carcinoma vescicale sarcomatoide associato a BKV in paziente trapiantato di rene: possibile ruolo dell’immunoistochimica per BKV-TAg e p16 su citologia urinaria nella diagnosi precoce di neoplasia 53
Natural history of renal metastases to the pancreas: do not operate all and always? 53
Validation of a Novel Three-Dimensional (3D Fusion) Gross Sampling Protocol for Clear Cell Renal Cell Carcinoma to Overcome Intratumoral Heterogeneity: The Meet-Uro 18 Study 53
Interleuchina-2 (IL-2) più Interferone-α (IFN-α) a basse dosi come terapia adiuvante nel carcinoma a cellule renali (RCC) operabile. Uno studio indipendente di fase III, randomizzato, multicentrico, del Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC) 52
Review on radiological evolution of COVID-19 pneumonia using computed tomography 52
Differential diagnosis of COVID-19 at the chest computed tomography scan: A review with special focus on cancer patients 52
The role of blood cholesterol quality in patients with advanced cancer receiving immune checkpoint inhibitors 51
A new modified sunitinib schedule for metastatic renal cell cancer (mRCC): A pilot study 51
Correlations between tumor-infiltrating and circulating lymphocyte subpopulations in mRCC patients treated with immune-checkpoint inhibitors 51
A wide skull osteolytic metastasis in advanced breast cancer 51
Small renal masses (≤ 4 cm): differentiation of oncocytoma from renal clear cell carcinoma using ratio of lesion to cortex attenuation and aorta–lesion attenuation difference (ALAD) on contrast-enhanced CT 51
Phase III, randomised, multicentre trial of maintenance immunotherapy with low-dose interleukin-2 and interferon-alpha for metastatic renal cell cancer 50
From the beginning to resistance: Study of plasma monitoring and resistance mechanisms in a cohort of patients treated with osimertinib for advanced T790M-positive NSCLC 50
Antiangiogenic tyrosine kinase inhibitors and immunotherapy as first-line treatment for metastatic renal cell carcinoma: is there an increased risk of hypothyroidism? 50
PD-L1 SNPs as biomarkers to define benefit in patients with advanced NSCLC treated with immune checkpoint inhibitors 49
Long-term clinical results with low-dose interleukin-2 and interferon-alpha in 145 patients with metastatic renal cell carcinoma” (Poster) 48
7 Tamoxifen vs tamoxifen plus 13-cis-retinoic acid vs tamoxifen plus interferon α-2° as first-line endocrine treatments in advanced breast cancer: updated results of a phase II, prospective, randomized multicentre trial 48
Diabete e neoplasie in una coorte di soggetti diabetici ospedalizzati 48
Long-term clinical results with low-dose Interleukin-2 and Interferon-α in 145 patients with metastatic renal cell carcinoma 48
TARIBO trial: Targeted therapy with or without nephrectomy in metastatic renal cell carcinoma (mRCC)-Liquid biopsy for biomarkers discovery 47
Fecal microbiota transplantation to improve efficacy of immune checkpoint inhibitors in renal cell carcinoma (TACITO trial) 47
Dynamic evolution of blood immune-inflammatory descriptors in advanced non-small cell lung cancer undergoing first-line immunotherapy-based regimens 46
Correlations Between the Immune-related Adverse Events Spectrum and Efficacy of Anti-PD1 Immunotherapy in NSCLC Patients 46
Very late recurrence of an apparently benign pheochromocytoma 46
Sopravvivenza e risposta alla terapia in 139 pazienti affetti da Carcinoma Renale Metastatico (CRm) trattati con Interleukina-2 (IL-2) ed Interferone Alfa (IFNα) a basse dosi. Influenza del rischio prognostico rilevato alla diagnosi 46
Retrospective analysis of patients undergoing stereotactic body radiotherapy (SBRT) in secondary non-bone lesions of metastatic renal cell carcinoma (mRCC) in treatment with vascular endothelial growth factor (VEGF) tyrosine kinase inhibitors 46
First-line pazopanib in patients with advanced non-clear cell renal carcinoma: An Italian case series 46
THE ROLE OF BLOOD CHOLESTEROL QUALITY IN PATIENTS WITH ADVANCED CANCER RECEIVING IMMUNE CHECKPOINT INHIBITORS 45
Role of Chemotherapy With Gemcitabine Plus 5-fluorouracil and Chemoimmunotherapy in Metastatic Renal Cell Cancer (mRCC) 45
BOLERO-3 results: Pharmacological activity or pharmacokinetic effect? 45
Dose-dense chemotherapy with Docetaxel, Cisplatin, folinic acid and 5-fluorouracil (TCAF DD) in metastatic gastric cancer (MGC): A feasibility study 45
Immunotherapy options in metastatic renal cell cancer: Where we are and where we are going 45
Clinical Outcomes of Patients with Advanced Cancer and Pre-Existing Autoimmune Diseases Treated with Anti-Programmed Death-1 Immunotherapy: A Real-World Transverse Study 44
Long-term results and health-related quality of life (QoL) after a bladder preservation program using chemotherapy plus radiotherapy in muscle invasive bladder cancer (BC). Effects of p53 and others predictive markers 44
High efficacy of sequential chemotherapy (CT) with dose-dense modified TCF regimen (TCF-DD) followed by CT with oxaliplatin, folinic acid (FA), 5-fluorouracil (5-FU) and irinotecan (COFFI) in metastatic gastric cancer (MGC) 44
Gefitinib plus interleukin-2 in advanced non-small cell lung cancer patients previously treated with chemotherapy 44
Abscopal effect after hypofractionated radiotherapy in metastatic renal cell carcinoma pretreated with pazopanib 44
Effect of concomitant medications with immune-modulatory properties on the outcomes of patients with advanced cancer treated with immune checkpoint inhibitors: development and validation of a novel prognostic index 43
Dose-dense chemotherapy (CT) with modified TCF regimen (TCF-DD) in metastatic gastric cancer (MGC): A phase II study 43
Enzalutamide activity in patients with metastatic castration resistant prostate cancer (mCRPC) previously responding to antiandrogen withdrawal syndrome (AWS): A preliminary report 43
Pemetrexed versus pemetrexed plus carboplatin in pretreated patients with advanced non-small cell lung cancer: a pooled analysis of two randomized trials 43
Enzalutamide activity in patients with metastatic castration resistant prostate cancer (mCRPC) previously responding to antiandrogen withdrawal syndrome (AWN): A preliminary report 43
Outcome and Safety of Sorafenib in Metastatic Renal Cell Carcinoma Dialysis Patients: A Systematic Review 43
The 'nivolution' in renal cell carcinoma: Behind the scenes of clinical trials 43
Phase III, randomised, multicentre trial of maintenance immunotherapy with low-dose interleukin-2 and interferon-α for metastatic renal cell cancer 43
Safety and efficacy of nivolumab for metastatic renal cell carcinoma (mRCC): Real world data from an Italian expanded access program (EAP) 42
Dose-dense chemotherapy (CT) with modified dose-dense TCF regimen (TCF-DD) in metastatic gastric cancer (MGC): update of a phase II study 42
Everolimus in the management of metastatic renal cell carcinoma: An evidence-based review of its place in therapy 42
Immunotherapy and Sonpavde score validation in advanced upper tract urothelial carcinoma: a retrospective study by the Italian Network for Research in Urologic-Oncology 42
A pilot phase II study of chemotherapy with oxaliplatin, folinic acid, 5-fluorouracil and irinotecan in metastatic gastric cancer 42
Chemotherapy in non-small cell lung cancer patients after prior immunotherapy: The multicenter retrospective CLARITY study 41
Circulating immune-profile as predictor of outcome in NSCLC patients treated with nivolumab 41
Bevacizumab (B) plus low-doses immunotherapy (IT) plus chemotherapy (CT) (BIC) in metastatic renal cell cancer (mRCC): Antitumor effects and variations of T-regulatory cells (Treg) and other T lymphocytes subsets. A study of the Italian Oncology Group for Clinical Research (GOIRC) 41
Adjuvant low-dose IL2 plus IFNα in operable renal cell carcinoma: a phase III, randomized, multicenter trial 41
Outcomes of post-progression therapies in patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC) progressing after docetaxel (DOC): Real-world data from an Italian multicenter observational study (ECHOS trial) 40
Clinicopathologic correlates of first-line pembrolizumab effectiveness in patients with advanced NSCLC and a PD-L1 expression of ≥ 50% 40
Palliative radiotherapy in advanced cancer patients treated with immune-checkpoint inhibitors: The practice study 40
Adjuvant low-dose interleukin-2 (IL2) plus interferone-alpha (IFN) in operable renal cell cancer (RCC). A phase III, randomized, multicenter, independent trial of the Italian Oncology Group for Clinical Research (GOIRC) 40
Gefitinib plus interleukin-2 in previously treated patients with advanced non-small-cell lung cancer (NSCLC) 40
Phase III, randomized, multicentre trial of maintenance of biotherapy with Interleukin-2 (IL-2) and Interferon-alpha (IFN) for metastatic renal cell cancer (RCC) 40
Author Correction: Validation of the GRade, Age, Nodes and Tumor (GRANT) score within the Surveillance Epidemiology and End Results (SEER) database: A new tool to predict survival in surgically treated renal cell carcinoma patients (Scientific Reports, (2019), 9, 1, (13218), 10.1038/s41598-019-49250-6) 40
Chemotherapy, targeted therapy and immunotherapy: Which drugs can be safely used in the solid organ transplant recipients? 40
Combining PARP Inhibitors and Androgen Receptor Signalling Inhibitors in Metastatic Prostate Cancer: A Quantitative Synthesis and Meta-analysis 39
A metanalysis on cabozantinib and bone metastases: True story or commercial gimmick? 39
Erythrocyte mean corpuscular volume change during pemetrexed treatment in advanced non small cell lung cancer patients 39
Renal metastases to pancreas: do not operate all and always? 39
Potential role of hypovitaminosis D in renal cell carcinoma patients treated with immune-checkpoint inhibitors 39
TARIBO trial: Cytoreductive nephrectomy in metastatic renal cell carcinoma patients treated with targeted agents 39
Final results of a dose-finding phase II trial with a triple combination therapy in metastatic renal cell cancer (MRCC): Bevacizumab (B) plus Immunotherapy (I) plus Chemotherapy (C) (BIC). Antitumor effects and variations of circulating T-regulatory cells (Treg) and other T lymphocytes subsets 39
Totale 5.210
Salva come PNG Salva come JPEG
Categoria #
all - tutte 68.555
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 68.555
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020212 0 0 20 4 16 40 22 21 19 43 19 8
2020/2021205 3 6 10 23 13 34 13 19 37 19 16 12
2021/20221.471 9 10 13 30 5 117 319 104 61 25 100 678
2022/20236.079 715 744 559 381 458 587 80 316 1.930 27 205 77
2023/20242.661 135 225 103 109 290 543 205 125 178 154 189 405
2024/20251.515 157 698 660 0 0 0 0 0 0 0 0 0
Totale 12.311